Material News

PTA-Adhoc: Biofrontera AG: Forecast Increase

Public disclosure of inside information according to article 17 MAR

Leverkusen (pta003/14.02.2026/13:15) - Biofrontera AG is raising its forecast for the fiscal year 2025. Based on preliminary figures, EBITDA is expected to be between EUR 3.5 million and EUR 5 million (previous expectation: EUR 1.5 million to EUR 3.5 million). The previous revenue forecast of EUR 17 million to EUR 20 million remains unchanged.

(end)

emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
country: Germany
contact person: Investor Relations
phone: +49 (0) 214 87 63 20
e-mail: ir@biofrontera.com
website: www.biofrontera.com

ISIN(s): DE000A4BGGM7 (share)
stock exchanges: regulated market in Dusseldorf, Frankfurt; free market in Munich, free market in Stuttgart; open market in Tradegate BSX

[ source: https://www.pressetext.com/news/20260214003 ]

Material News archive

2025

PTA-Adhoc: Biofrontera AG: Forecast Increase

Public disclosure of inside information according to article 17 MAR

Leverkusen (pta003/14.02.2026/13:15) - Biofrontera AG is raising its forecast for the fiscal year 2025. Based on preliminary figures, EBITDA is expected to be between EUR 3.5 million and EUR 5 million (previous expectation: EUR 1.5 million to EUR 3.5 million). The previous revenue forecast of EUR 17 million to EUR 20 million remains unchanged.

(end)

emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
country: Germany
contact person: Investor Relations
phone: +49 (0) 214 87 63 20
e-mail: ir@biofrontera.com
website: www.biofrontera.com

ISIN(s): DE000A4BGGM7 (share)
stock exchanges: regulated market in Dusseldorf, Frankfurt; free market in Munich, free market in Stuttgart; open market in Tradegate BSX

[ source: https://www.pressetext.com/news/20260214003 ]

2024

PTA-Adhoc: Biofrontera AG: Forecast Increase

Public disclosure of inside information according to article 17 MAR

Leverkusen (pta003/14.02.2026/13:15) - Biofrontera AG is raising its forecast for the fiscal year 2025. Based on preliminary figures, EBITDA is expected to be between EUR 3.5 million and EUR 5 million (previous expectation: EUR 1.5 million to EUR 3.5 million). The previous revenue forecast of EUR 17 million to EUR 20 million remains unchanged.

(end)

emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
country: Germany
contact person: Investor Relations
phone: +49 (0) 214 87 63 20
e-mail: ir@biofrontera.com
website: www.biofrontera.com

ISIN(s): DE000A4BGGM7 (share)
stock exchanges: regulated market in Dusseldorf, Frankfurt; free market in Munich, free market in Stuttgart; open market in Tradegate BSX

[ source: https://www.pressetext.com/news/20260214003 ]

2023

PTA-Adhoc: Biofrontera AG: Forecast Increase

Public disclosure of inside information according to article 17 MAR

Leverkusen (pta003/14.02.2026/13:15) - Biofrontera AG is raising its forecast for the fiscal year 2025. Based on preliminary figures, EBITDA is expected to be between EUR 3.5 million and EUR 5 million (previous expectation: EUR 1.5 million to EUR 3.5 million). The previous revenue forecast of EUR 17 million to EUR 20 million remains unchanged.

(end)

emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
country: Germany
contact person: Investor Relations
phone: +49 (0) 214 87 63 20
e-mail: ir@biofrontera.com
website: www.biofrontera.com

ISIN(s): DE000A4BGGM7 (share)
stock exchanges: regulated market in Dusseldorf, Frankfurt; free market in Munich, free market in Stuttgart; open market in Tradegate BSX

[ source: https://www.pressetext.com/news/20260214003 ]

2022

PTA-Adhoc: Biofrontera AG: Forecast Increase

Public disclosure of inside information according to article 17 MAR

Leverkusen (pta003/14.02.2026/13:15) - Biofrontera AG is raising its forecast for the fiscal year 2025. Based on preliminary figures, EBITDA is expected to be between EUR 3.5 million and EUR 5 million (previous expectation: EUR 1.5 million to EUR 3.5 million). The previous revenue forecast of EUR 17 million to EUR 20 million remains unchanged.

(end)

emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
country: Germany
contact person: Investor Relations
phone: +49 (0) 214 87 63 20
e-mail: ir@biofrontera.com
website: www.biofrontera.com

ISIN(s): DE000A4BGGM7 (share)
stock exchanges: regulated market in Dusseldorf, Frankfurt; free market in Munich, free market in Stuttgart; open market in Tradegate BSX

[ source: https://www.pressetext.com/news/20260214003 ]

2021

PTA-Adhoc: Biofrontera AG: Forecast Increase

Public disclosure of inside information according to article 17 MAR

Leverkusen (pta003/14.02.2026/13:15) - Biofrontera AG is raising its forecast for the fiscal year 2025. Based on preliminary figures, EBITDA is expected to be between EUR 3.5 million and EUR 5 million (previous expectation: EUR 1.5 million to EUR 3.5 million). The previous revenue forecast of EUR 17 million to EUR 20 million remains unchanged.

(end)

emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
country: Germany
contact person: Investor Relations
phone: +49 (0) 214 87 63 20
e-mail: ir@biofrontera.com
website: www.biofrontera.com

ISIN(s): DE000A4BGGM7 (share)
stock exchanges: regulated market in Dusseldorf, Frankfurt; free market in Munich, free market in Stuttgart; open market in Tradegate BSX

[ source: https://www.pressetext.com/news/20260214003 ]

Ad Hoc News PDF archive

2020 (since April 2020)

PTA-Adhoc: Biofrontera AG: Forecast Increase

Public disclosure of inside information according to article 17 MAR

Leverkusen (pta003/14.02.2026/13:15) - Biofrontera AG is raising its forecast for the fiscal year 2025. Based on preliminary figures, EBITDA is expected to be between EUR 3.5 million and EUR 5 million (previous expectation: EUR 1.5 million to EUR 3.5 million). The previous revenue forecast of EUR 17 million to EUR 20 million remains unchanged.

(end)

emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
country: Germany
contact person: Investor Relations
phone: +49 (0) 214 87 63 20
e-mail: ir@biofrontera.com
website: www.biofrontera.com

ISIN(s): DE000A4BGGM7 (share)
stock exchanges: regulated market in Dusseldorf, Frankfurt; free market in Munich, free market in Stuttgart; open market in Tradegate BSX

[ source: https://www.pressetext.com/news/20260214003 ]